Related Experiment Video

Updated: Apr 7, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.8K

Treatment Considerations for Unique Patient Populations With HCV Genotype 1 Infection

Kimberly A Toussaint-Miller1, Jennifer Andres2

  • 1Temple University School of Pharmacy, Philadelphia, PA, USA toussaka@temple.edu.

The Annals of Pharmacotherapy
|July 4, 2015
PubMed

Insights

Direct-acting antivirals are recommended for hepatitis C virus (HCV) genotype 1. Treatment requires careful consideration of specific patient populations, including those with liver disease, HIV, or coinfections.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Hepatitis C virus (HCV) genotype 1 infection presents unique challenges in specific patient groups.
  • Effective treatment strategies require tailored approaches beyond standard protocols.

Purpose of the Study:

  • To systematically review the literature on treating HCV genotype 1 in patient populations needing special consideration.
  • To identify key factors influencing therapy initiation and management in these diverse groups.

Main Methods:

  • A comprehensive literature search was conducted using MEDLINE and other databases.
  • Studies published between January 1985 and March 2015 were included, focusing on direct-acting antiviral therapies.
  • Data extraction focused on efficacy, drug interactions, and adverse effects in specific populations.

Main Results:

  • Direct-acting antivirals (DAAs) are the recommended first-line treatment for HCV genotype 1.
  • Specific DAA combinations include sofosbuvir, simeprevir, ledipasvir/sofosbuvir, and others.
  • Efficacy and safety data were analyzed for patients with decompensated cirrhosis, post-transplant, HIV coinfection, African Americans, obesity, hepatitis B coinfection, renal impairment, pregnancy, and pediatrics.

Conclusions:

  • Treatment decisions for HCV genotype 1 must be individualized based on patient population.
  • Clinicians must carefully assess potential drug interactions and adverse effects.
  • Tailored therapeutic strategies are crucial for optimizing outcomes in complex patient cases.
Abstract

Keywords:
HIV/AIDSdrug interactionshepatitis Cinfectious diseasestransplants

More Related Videos

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.4K
Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors16:49

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors

Published on: July 16, 2012

12.1K

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
46
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.7K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
347
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
32
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
748
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
298